Abstract:Alzheimer's disease (AD) is the most common form of dementia, and the molecular mechanisms that underlie AD pathophysiology remain unclear. AMP-activated protein kinase (AMPK) is a Ser/Thr kinase that functions as a central energy sensor to maintain cellular energy homeostasis. Furthermore, AMPK integrates several signaling pathways controlling de novo protein synthesis (mRNA translation) which is vital for long-term synaptic plasticity and memory formation. Dysregulation of energy homeostasis and de novo protein synthesis are both implicated in AD. AMPK is a heterotrimeric protein with a catalytic α subunit and regulatory β/γ subunit. The α subunit of AMPK exists in two isoforms: α1 and α2, and their roles in AD are unknown. Post Mortem brain tissue from human AD was examined by both western blot and immunohistochemistry for AMPKα1 and AMPKα2 levels. AMPKα1 protein levels were selectively reduced in late development in the forebrain of Tg19959 AD model mice to generate AMPKα1(+/-)/Tg19959 double mutant mice. These mice were cognitively assessed by Morris Water Maze (MWM) and Novel Object Recognition (NOR) tasks. Hippocampal long-term potentiation (LTP) was measured to assess synaptic plasticity, moreover dendritic spine morphology was examined by Golgi Stain. In human hippocampal tissue AMPKα1 levels were dramatically increased, while levels of AMPKα2 were decreased in comparison with age-matched controls. These changes were neuronally localized and AD hippocampi specific. AD associated impairments of cognition and synaptic plasticity were alleviated in AMPKα1(+/-)/Tg19959 double mutant mice. Analysis of dendritic spine morphology revealed the hippocampal abnormalities in theTg19959 model mice were restored with genetic reduction of AMPKα1. AMPKα1 is abnormally neuronally upregulated in AD. Our results demonstrate that restoration of AMPKα1 levels in an AD model mouse ameliorates the behavioral and synaptic plasticity impairments. Our findings indicate AMPKα1 dysregulation as a molecular mechanism underlying AD pathophysiology, and providing insights into a potential therapeutic strategy.

Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer’s Disease

Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid Β

Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

P2‐157: BRAIN‐SPECIFIC REPRESSION OF AMPKα1 ALLEVIATES MEMORY DEFICITS AND SYNAPTIC FAILURE IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer's model mice.

Brain-specific repression of AMPK1 alleviates pathophysiology in Alzheimer's model mice

Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action

AMPA receptors in Alzheimer disease: Pathological changes and potential therapeutic targets

Highlighting the protective or degenerative role of AMPK activators in dementia experimental models.

AMPK-mediated regulation of neuronal metabolism and function in brain diseases

Neuronal AMP-activated protein kinase hyper-activation induces synaptic loss by an autophagy-mediated process

AMPK Ameliorates Tau Acetylation and Memory Impairment Through Sirt1

Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives

Autophagy Modulation for Alzheimer's Disease Therapy.

Isoform-specific dysregulation of AMP-activated protein kinase signaling in a non-human primate model of Alzheimer's disease

Effect of AMPKα2 Knockdown on Alzheimer's Pathogenesis and Cognitive Deficits in Young Tg19959 Mice.

Mitochondria-associated membranes (MAMs): a potential therapeutic target for treating Alzheimer's disease

Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer's Disease: Recent Advances and Therapeutic Implications

The old second messenger cAMP teams up with novel cell death mechanisms: potential translational therapeutical benefit for Alzheimer's disease and Parkinson's disease

Targeting the Mtor Signaling Network for Alzheimer'S Disease Therapy

Antagonists Targeting Eef2 Kinase Rescue Multiple Aspects of Pathophysiology in Alzheimer's Disease Model Mice